<DOC>
	<DOCNO>NCT00001094</DOCNO>
	<brief_summary>To compare long-term virologic response combination therapy two protease inhibitor , i.e. , nelfinavir ( NFV ) + saquinavir soft gel capsule ( SQVsgc ) delavirdine ( DLV ) combination lamivudine/zidovudine ( 3TC/ZDV , Combivir ) versus NFV 3TC/ZDV , proportion patient demonstrate virologic success ( &lt; 500 copies/ml HIV RNA ) week 48 , without prior virologic clinical failure . To evaluate safety tolerance combination protease inhibitor . To evaluate durability virologic response assess Roche Ultra Sensitive assay ( &lt; 200 copies/ml ) culturable virus . To compare time confirm virologic response ( two consecutive plasma HIV RNA level &lt; 500 copies/ml ) confirm treatment relapse follow confirm virologic response across treatment arm . To evaluate biologic phenotype ( non-syncytium inducing versus syncytium induce capacity ) evolution pattern viral resistance among patient confirm treatment failure week 16 24 . To compare immunologic benefit , measure longitudinal CD4/CD8 cell count profile . To evaluate influence baseline virologic immunologic parameter magnitude duration plasma HIV RNA response . To compare virologic response two dose schedule NFV SQVsgc ( bid vs tid ) NFV SQVsgc either DLV combination 3TC/ZDV . To evaluate compliance exploratory population pharmacometrics . Past study show combination therapy result well clinical outcome may prolong effect therapy . The enhanced effect see combination therapy likely relate great suppression HIV replication alteration resistance pattern . Both vitro vivo study suggest triple-drug therapy may advantage one- two-drug regimen . Therefore , triple-drug therapy appear important strategy treatment HIV infection .</brief_summary>
	<brief_title>A Comparison Nelfinavir Plus Saquinavir Plus Delavirdine 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV HIV-Infected Patients</brief_title>
	<detailed_description>Past study show combination therapy result well clinical outcome may prolong effect therapy . The enhanced effect see combination therapy likely relate great suppression HIV replication alteration resistance pattern . Both vitro vivo study suggest triple-drug therapy may advantage one- two-drug regimen . Therefore , triple-drug therapy appear important strategy treatment HIV infection . This Phase II , randomize , control , open-label trial NFV + SQVsgc either DLV combine 3TC/ZDV versus NFV combine 3TC/ZDV . Prior randomization , patient stratify HIV RNA ( 65,000 copies/ml ) prior antiretroviral therapy ( therapy v therapy ) . Patients ( 100 patients/arm ) randomly assign one four arm . Arm I receive NFV plus combination 3TC/ZDV . Arm II receive NFV plus SQVsgc plus combination 3TC/ZDV . Arm III receive NFV plus SQVsgc plus DLV . Arm IV receive NFV plus SQVsgc plus DLV . Treatment continue 48 week follow enrollment last patient . Response treatment assess week 16 . Patients confirm plasma HIV RNA level &gt; = 500 copies/ml week 16 whose plasma HIV RNA decrease since study entry ( day 0 ) may continue therapy reassess week 20 24 . Patients consider treatment failure ( i.e. , 2 consecutive plasma HIV RNA level &gt; = 500 copies/ml week 16 ) relapse may register Step 2 treatment ( addition least 2 new drug prior treatment regimen ) , enroll another ACTG protocol time failure , seek best available therapy continue follow remainder study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>This study terminate .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>